4.1 Article

Inflammatory and Toxic Myopathy

Journal

SEMINARS IN NEUROLOGY
Volume 32, Issue 5, Pages 491-499

Publisher

THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0033-1334467

Keywords

myositis; polymyositis; dermatomyositis; inclusion body myositis; necrotizing myopathy; toxic myopathy; cholesterol-lowering agent myopathy

Ask authors/readers for more resources

Although muscle diseases are relatively rare, several treatable myopathies must be recognized by the clinician to maximize the possibility of restoring strength in affected patients. The inflammatory myopathies, including polymyositis, dermatomyositis, inflammatory necrotizing myopathy; and myositis in association with mixed connective tissue disease, typically respond well to immunosuppressive treatment. Inclusion body myositis, a myopathy that has features of both inflammation and primary degeneration, may not be treatable at this time, but treatments are actively being sought. Muscle dysfunction caused by toxins must also be recognized because removal of the offending toxin usually results in restoration of normal muscle function. Important muscle toxins include cholesterol-lowering medications, colchicine, zidovudine, corticosteroids, emetine, and ethanol.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available